Seeking Alpha

Threshold Pharmaceuticals (THLD +7.2% to $4.78) receives an upgrade to Overweight from Neutral...

Threshold Pharmaceuticals (THLD +7.2% to $4.78) receives an upgrade to Overweight from Neutral from Piper Jaffray, which is impressed with the differentiation of Threshold's TH-302 drug for soft-tissue sarcoma compared with a rival product. Piper also believes that Threshold's hypoxia-activation platform will be able to be used to treat a wide range of cancers. Piper doubled the company's price target to $10.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs